Update Epilepsie

Zusammenfassung

In der Epileptologie hat sich eine intensive Diskussion zur Klassifikation epileptischer Anfälle und Syndrome entwickelt, die noch nicht abgeschlossen ist. Sie reflektiert die erheblichen Fortschritte, die im Verständnis der Ätiologie und Pathophysiologie gewonnen wurden, aber auch den lange noch nicht abgeschlossenen Erkenntniszugewinn. Weitere Modifikationen sind daher zwingend zu erwarten. Die diagnostischen Möglichkeiten haben sich weiter verbessert. Hauptproblem ist, dass sie nicht angemessen angewendet werden. Die Grundsätze der Epilepsietherapie haben sich in letzter Zeit nicht verändert. Es hat sich gezeigt, dass Lamotrigin und Levetiracetam zu den Standardantikonvulsiva werden. Neueste Antikonvulsiva haben zum Teil überzeugt. Leider wird ihre nachhaltige Anwendung in Deutschland im Gegensatz zum Rest der Welt durch die Auswirkungen des Arzneimittelmarktneuordnungsgesetzes praktisch verhindert. Neurostimulationsverfahren bieten interessante Perspektiven, aber nicht mehr.

 

MissingLinkText

Summary

There has been an ongoing and vivid discussion about the classification of epileptic seizures and syndromes that has not been finished yet. It reflects the substantial progress of understanding etiology and pathophysiology but also the preliminary character of this knowledge. Further modifications are to be expected. The diagnostic possibilities have advanced. The major problem is that these ameliorations are not widely used. The basic rules of anticonvulsant treatment remained the same. It is apparent that lamotrigine and levetiracetam are the modern standard anticonvulsant drugs. The latest anticonvulsant drugs are only partial improvements. Unfortunately, their sustained availability is prevented by the consequences of new regulatory laws in Germany. Neurostimulation methods offer interesting perspectives, not more and not less.

 

MissingLinkText

Schlüsselwörter

Epilepsie - Klassifikation - Diagnostik - Therapie - Update

Keywords

Epilepsy - classification - diagnostics - therapy - update

 

 

MissingLinkText

Interessenkonflikt

Bernhard J. Steinhoff hat honorarpflichtig Vorträge für Eisai und UCB gehalten. Er hat Beraterfunktionen für die Firmen Actelion, Bial, B. Braun, Melsungen, Desitin, Eisai und UCB wahrgenommen.

• Literatur

• 1 Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 498-501.
• 2 Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
• 3 Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 796-803.
• 4 Engel J. Report of the ILAE Classification Core Group. Epilepsia 2006; 47: 1558-1568.
• 5 Steinhoff B, Krämer G. Revidierte Terminologie und neue Konzepte zur Einteilung von epileptischen Anfällen und Epilepsien. Neue Empfehlungen. Muss das wirklich sein?. Z Epileptol 2010; 23: 225-226.
• 6 Blume WT. et al. Glossary of descriptive terminology for ictal semiology: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 1212-1218.
• 7 Berg AT. et al. Revides terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010; 51: 676-685.
• 8 Lüders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology?. Epilepsia 2009; 50: 1336-43.
• 9 Wellmer J. et al. Proposal for a magnetic resonance imaging protocol for the detection of epileptogenic lesions at early outpatient stages. Epilepsia 2013; 54: 1977-1987.
• 10 Von Oertzen J. et al. Standard magnetic resonance imaging is inadequate for patients with refractory focal epilepsy. J Neurol Neurosurg Psychiatry 2002; 73: 643-647.
• 11 Steinhoff BJ. et al. The impact of guidelines on the quality of MRI diagnostics in adult patients referred to a tertiary Epilepsy Centre. J Neurol 2013; 260: 2174-2175.
• 12 Steinhoff BJ. Antikonvulsive Pharmakotherapie Jugendlicher und Erwachsener. State of the art. Z Epileptol 2013; 26: 142-153.
• 13 Schmidt D. Pharmacotherapy of epilepsy – current problems and controversies. Fortschr Neurol Psychiat 1983; 51: 363-86.
• 14 Schmidt D. Drug treatment of epilepsy: Options and limitations. Epilepsy Behav 2009; 15: 56-65.
• 15 Baumgartner C. et al. Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. In: Diener HC, Weimar C, Berlit P. et al. (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2012: 28-47
• 16 Steinhoff BJ, Kurth C, Dennig D. Levetiracetam bei generalisierten Epilepsien des Erwachsenenalters. Praktische Erfahrungen mit dem Einsatz außerhalb der Zulassung. Z Epileptol 2012; 25: 118-24.
• 17 Tomson T. et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015; 56: 1006-1019.
• 18 Baker G. et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84: 382-390.
• 19 Steinhoff BJ. Der Epilepsiepatient in der Praxis. Basel: ComMed Verlagsagentur; 2005
• 20 Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62 (04) 382-9.
• 21 Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62 (04) 375-81.
• 22 Steinhoff BJ, Staack AM, Wisniewski I. Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disord 2012; 14: 379-387.
• 23 Rosenow F. et al. The LaLiMo trial: lamotrigine compared with levetircatem in the initial 26 weeks of monotherapy for focal and generalised epilepsy – an open-label, prospective, randomised controlled multicenter Study. J Neurol Neurosurg Psychiatry 2012; 83: 1093-8.
• 24 Trinka E. et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013; 84: 1138-1147.
• 25 Privitera MD. et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175.
• 26 Steinhoff BJ. et al. The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure 2005; 14: 597-605.
• 27 Rowan AJ. et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine and carbamazepine. Neurology 2005; 64: 1868-1873.
• 28 Ficker DM. et al. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005; 65: 593-5.
• 29 Saetre E. et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-1302.
• 30 Werhahn K. et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015; 56: 450-459.
• 31 Doeser A. et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain 2015; 138: 371-387.
• 32 Klitgaard H. et al. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 2016; 57: 538-548.
• 33 Doty P. et al. Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci 2013; 1291: 56-68.
• 34 Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf 2013; 12: 847-855.
• 35 Nass RD. et al. Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany. Epilepsy Behav 2016; 56: 54-58.
• 36 Correia FD. et al. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study. Epilepsy Res 2014; 108: 1399-1405.
• 37 Villanueva V. et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res 2014; 108: 1243-1252.
• 38 Runge U. et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Epilepsia 2015; 56: 1921-1930.
• 39 Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand 2016; 133: 160-172.
• 40 Bauer S. et al. Transcutaneous vagus nerve stimulation (tVNS) for treatment of drug-resistant epilepsy: A randomized, double-blind clinical trial (cMPsE02). Brain Stimul. 2016 EPUB ahead of print
• 41 Soss J. et al. A prospective long-term study of external trigeminal stimulation for drug-resistant epilepsy. Epilepsy Behav 2015; 42: 44-47.